Aoxing Pharmaceutical Company, Inc. announced earnings results for the third quarter and nine months ended March 31, 2014. For the quarter, the company reported revenues of $2,445,793, representing a 30% increase over the revenues realized in the comparable periods of fiscal year 2013. The increase in revenue was mainly attributable to the increase in sales of main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market. Loss from operations of $717,874 during the three months was only 31% of the loss from operations realized in the prior year's third quarter. After that deduction, the company realized a net loss attributable to the shareholders was $1,822,137, representing improvements of 30%.

For the nine months, the company reported revenue of $9,489,708, representing 22% increase over the revenues realized in the comparable periods of fiscal year 2013. Loss from operations of $2,625,798 was only 58% of the loss from operations realized in the comparable period of fiscal 2013. The primary reason for the reduction in loss from operations was the elimination of a television advertising program carried out during fiscal 2013, with resulting reductions in selling expense of $2,103,722 and $1,541,806 during the three and nine month periods ending March 31, 2014. the company realized a net loss attributable to the shareholders was $5,882,840, representing improvements of 2% for the same period a year ago.